StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$9.95−0.62 (-5.87%)

Close on Nov 20, 2026Market cap $7.94BP/E –Yield –

Summit Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Summit Therapeutics's pe ratio was 3.5× on Jan 31, 2022, against 11.0× a year earlier. Over the last 3 years it ranged from 2.0× to 12.7×, with a median of 5.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Jan 31, 20223.5×−0.8
2021Dec 31, 20214.3×−3.2
2020Dec 31, 20207.5×+4.9
2019Dec 31, 20192.5×–

More Summit Therapeutics figures

See a number that looks wrong?